Cargando…

Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhongjie, Liu, Ying, Qiu, Lixia, Fan, Zuopeng, Nie, Wei, Liang, Shan, Jin, Ronghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683707/
https://www.ncbi.nlm.nih.gov/pubmed/26684004
http://dx.doi.org/10.1186/s12985-015-0451-9
_version_ 1782406068231471104
author Hu, Zhongjie
Liu, Ying
Qiu, Lixia
Fan, Zuopeng
Nie, Wei
Liang, Shan
Jin, Ronghua
author_facet Hu, Zhongjie
Liu, Ying
Qiu, Lixia
Fan, Zuopeng
Nie, Wei
Liang, Shan
Jin, Ronghua
author_sort Hu, Zhongjie
collection PubMed
description BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFNα/RBV treatment. METHODS: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFNα/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. RESULTS: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. CONCLUSIONS: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFNα/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFNα was not observed.
format Online
Article
Text
id pubmed-4683707
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46837072015-12-19 Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy Hu, Zhongjie Liu, Ying Qiu, Lixia Fan, Zuopeng Nie, Wei Liang, Shan Jin, Ronghua Virol J Research BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFNα/RBV treatment. METHODS: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFNα/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. RESULTS: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. CONCLUSIONS: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFNα/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFNα was not observed. BioMed Central 2015-12-18 /pmc/articles/PMC4683707/ /pubmed/26684004 http://dx.doi.org/10.1186/s12985-015-0451-9 Text en © Hu et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hu, Zhongjie
Liu, Ying
Qiu, Lixia
Fan, Zuopeng
Nie, Wei
Liang, Shan
Jin, Ronghua
Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
title Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
title_full Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
title_fullStr Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
title_full_unstemmed Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
title_short Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
title_sort kinetic response of wild and mutant core codon 70 strains of hcv genotype 1b to pegylated interferon-α and ribavirin therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683707/
https://www.ncbi.nlm.nih.gov/pubmed/26684004
http://dx.doi.org/10.1186/s12985-015-0451-9
work_keys_str_mv AT huzhongjie kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy
AT liuying kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy
AT qiulixia kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy
AT fanzuopeng kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy
AT niewei kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy
AT liangshan kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy
AT jinronghua kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy